Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Seeks Weight-Of-Evidence Standard For Drug Approvals

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug reviewers should be able to consider efficacy evidence beyond double-blind, randomized controlled trials, the group says in proposals to stimulate biomedical innovation.
Advertisement

Related Content

FDA Approval Standards Need To Be Relaxed, Venture Capitalists Say
FDA Approval Standards Need To Be Relaxed, Venture Capitalists Say
Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011
Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011
BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA
BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA
BIO's "Big Ideas" Include Expanding FDA's Mission, Allowing "Progressive Approval"
BIO's "Big Ideas" Include Expanding FDA's Mission, Allowing "Progressive Approval"

Topics

Advertisement
UsernamePublicRestriction

Register

PS072441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel